ARECOR THERAPEUTICS PLC (AREC) — Investor Presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to the ARECOR THERAPEUTICS PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted any time via the Q and A tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company will review all questions submitted today and publish responses where it is appropriate to do so, and these will be available via your Investor Meet company dashboard. Before we begin, I would like to submit the following poll, and I would now like to hand you over to CEO, Sarah Howe. Good afternoon, Sarah. Great. Thank you, and good afternoon, everybody. Thank you for joining us today. So, my name is Sarah Howell. I'm the CEO of ARECOR, and I'm joined today, by Susan Lather, who's our CFO. And we'll talk you through today the interim results for the six months ending June 30, 2023. So I'll just draw your attention very briefly to, our customary legal notice. So by way of background at ARECOR THERAPEUTICS, for those of you that may be joining us for the first time today, we're very much focused on improving patient care by enhancing existing therapeutic medicines such that they're safer, more effective, and easier to use. And we do this by leveraging our innovative and proprietary formulation technology platform, Aristat. And we use this platform to develop these enhanced and differentiated versions of existing therapeutic medicines. So during this slide, really, what I want to talk you through is the vision for the business and how we see generating value and gro...